A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Clinical trial NCT07610798 · RECRUITING

Trial details

NCT number: NCT07610798
Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advance Solid Tumors Colon and Rectal Cancer Non - Small Cell Lung Cancer NSCLC Pancreatic Adenocarcinoma Advanced or Metastatic Ovarian Cancer Endometrial Cancer Biliary Cancers

Start date: 2026-06-01
Primary completion: 2029-05-01
Enrollment: 178

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.